[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J].Ca A Cancer Journal for Clinicians,2018,60(5):277-300.
[2] MATSUDA T,SAIKA K.Trends in liver cancer mortality rates in Japan,USA,UK,France and Korea based on the WHO mortality database[J].Japanese Journal of Clinical Oncology,2012,42(4):360.
[3] YU S J.A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world:2010-2016[J].Clinical & Molecular Hepatology,2016,22(1):7-17.
[4] SPRINZL M F,GALLE P R.Current progress in immunotherapy of hepatocellular carcinoma[J].Journal of Hepatology,2017,66(3):482-484.
[5] ROTTE A,JIN J Y,LEMAIRE V.Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy[J].Annals of Oncology,2018,29(1):71-83.
[6] MOEINI A,CORNELLÀ H,VILLANUEVA A.Emerging signaling pathways in hepatocellular carcinoma[J].Liver Cancer,2012,1(2):83-93.
[7] DHANASEKARAN R,BANDOH S,ROBERTS L R.Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances[J].F1000research,2016,5:879-894.
[8] LLOVET J M,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].New Engl J Med,2008,359(4):378-390.
[9] CHENG A L,KANG Y K,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase Ⅲ randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
[10] YAMAMOTO L,MATSUI J J,MATSUSHIMA T,et al.Lenvatinib,an angiogenesis inhibitor targeting VEGFR/FGFR,shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage[J].Vascular Cell,2014,6(1):18.
[11] SCHLUMBERGER M,TAHARA M, LORI J,et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J].New England Journal of Medicine,2015,372(7):621-630.
[12] MOTZER R J,HUTSON T E,GLEN H,et al.Lenvatinib,everolimus,and the combination in patients with metastatic renal cell carcinoma:a randomised,phase 2,open-label,multicentre trial.[J].Lancet Oncology,2015,16(15):1473-1482.
[13] IKEDA K,KUDO M,KAWAZOE S,et al.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J].Journal of Gastroenterology,2017,52(4):512-519.
[14] KUDO M,FINN R S,QIN S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J].Lancet,2018,391:1163-1173.
[15] CHENG A L,KANG Y K,LIN D Y,et al.Sunitinib versus sorafenib in advanced hepatocellular cancer:results of a randomized phase Ⅲ trial.[J].Journal of Clinical Oncology,2013,31(32):4067-4075.
[16] JOHNSON P J,QIN S,PARK J W,et al.Brivanib versus sorafenib as first-line therapy in patients with unresectable,advanced hepatocellular carcinoma:results from the randomized phase Ⅲ BRISK-FL study[J].Journal of Clinical Oncology,2013,56(6):3517-3524.
[17] CAINAP C,QIN S,HUANG W T,et al.Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma:results of a randomized phase Ⅲ trial[J].Journal of Clinical Oncology,2015,33(2):172-179.
[18] ZHU A X,ROSMORDUC O,EVANS T R J,et al.Search:a phase Ⅲ,randomized,double-blind,placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma[J].Journal of Clinical Oncology,2015,33(6):559-566.
[19] BRUIX J,TAK W,GASBARRINI A,et al.Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma:multicentre,open-label,phase Ⅱ safety study[J].European Journal of Cancer,2013,49(16):3412-3419.
[20] BRUIX J,QIN S,MERLE P,et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2016,389(10064):56-66.
[21] LLOVET J M,DECAENS T,RAOUL J L,et al.Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed:results from the randomized phase Ⅲ BRISK-PS study[J].Journal of Clinical Oncology,2013,31(28):3509-3516.
[22] ZHU A X,KUDO M,ASSENAT E,et al.Effect of Everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib:the EVOLVE-1 randomized clinical trial[J].Journal of the American Medical Association,2014,312(1):57-67.
[23] ZHU A X,PARK J O,RYOO B Y,et al.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH):a randomised,double-blind,multicentre,phase 3 trial.[J].Lancet Oncology,2015,16(7):859-870.
[24] KELLEY R K,VERSLYPE C,COHN A L,et al.Cabozantinib in hepatocellular carcinoma:results of a phase 2 placebo-controlled randomized discontinuation study[J].Annals of Oncology,2017,28(3):528-534.
[25] ABOUALFA G K,MEYER T,CHENG A L,et al.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J].New England Journal of Medicine,2018,379(1):54-63.
[26] ZHU A X,KANG Y K,YEN C J,et al.REACH-2:a randomized,doubleblind,placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellularcarcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib[J].J Clin Oncol,2018,36(suppl):abstr4003.
[27] LI J,ZHAO X,CHEN L,et al.Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J].BMC Cancer,2010,10(1):529-536.
[28] 秦叔逵,白玉贤,欧阳学农,等.阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床试验[J].临床肿瘤学杂志,2017,22(12):1057-1065.
[29] LU W,JIN X L,YANG C,et al.Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma:a single-center randomized controlled trial[J].Cancer Biology & Therapy,2017,18(6):433-438.
[30] 于俊岩,郭红亮,田向阳,等.甲磺酸阿帕替尼联合经导管动脉化疗栓塞治疗肝细胞肝癌的Ⅱ期临床试验[J].东南大学学报(医学版),2018,37(1):74-77.
[31] ESKANDER R N,LONGORIA T C.Immune checkpoint inhibition:therapeutic implications in epithelial ovarian cancer[J].Recent Patents on Anti-Cancer Drug Discovery,2015,10(2):133-144.
[32] PRIETO J,MELERO I.Immunological landscape and immunotherapy of hepatocellular carcinoma[J].Nature Reviews.Gastroenterology & Hepatology,2015,12(12):681-700.
[33] TANEJA S S.Re:safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J].J Urol,2015,67(4):816-817.
[34] EL-KHOUEIRY A B,SANGRO B,YAU T,et al.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J].Lancet,2017,389(10088):2492-2502.
[35] FLYNN M J,SAYED A A,SHARMA R,et al.Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma[J].Hepatology,2019,69:2258-2270.
[36] ZHU A X,FINN R S, EDELINE J,et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224):a non-randomised,open-label phase 2 trial[J].The Lancet Oncology,2018,19(7):940-952.
[37] WALKER L S K,SANSOM D M.The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses[J].Nature Reviews Immunology,2011,11(12):852-863.
[38] CALABR L,MORRA A,FONSATTI E,et al.Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma:an open-label,single-arm,phase 2 trial[J].The Lancet Oncology,2013,14(11):1104-1111. |
